Brazilian flora, especially in the Brazilian coastal rain forest, remains poorly studied regarding its chemical and pharmacological potential. A recent study published by our group indicates that Nidularium procerum, the most common representative of the bromeliaceae family, has potent analgesic and anti-inflammatory activities. 1) Bromeliaceae, one of the largest botanical families of the New World, is extensively distributed in tropical America. 2) This family comprises 46 genera encompassing about 2500 species from which 20 genera and 245 species are found in the State of Rio de Janeiro. The Brazilian coastal rain forest is the preferred habitat of Bromeliaceae (81.8%) where the greatest genetic diversity and the highest degree of endemism is found. 3) Species of Nidularium are well spread in the coastal rain forest from Bahia State, in the northeast region of Brazil, to Rio Grande do Sul State in the south. 4) Our previous results indicate that N. procerum extracts have strong analgesic activity, which is not associated with the activation of opioid receptors, but is mechanistically due to a selective inhibition of PGE 2 production. 1) In addition, we showed that the aqueous extract of N. procerum leaves (LAE) inhibited LPS-induced neutrophil accumulation in the mouse pleural cavity, but the molecular mechanism for this anti-inflammatory effect was not investigated. 1) Here, we investigated the mechanisms involved in the anti-inflammatory effects of N. procerum aqueous extract on the LPS-induced pleurisy model. We showed that in addition to LPS-induced neutrophil influx, N. procerum also inhibited LPS-driven in vivo neutrophil activation (as attested by inhibition of lipid body formation) and PAF-and fMLP-induced pleural neutrophilia. The mechanisms involved in N. procerum-mediated inhibition of neutrophil recruitment appear to involve decreased production of key inflammatory mediators of LPSdriven response, such as PGE 2 and inflammatory cytokines (IL-1 and IL-6), and an impaired locomotory activity of migrating neutrophils.
Committee.
Pleurisy Pleurisy was induced by intrathoracic (i.t.) injection of different stimuli, and the control group was injected with vehicle (sterile saline). Treatments were administered 1 h before stimulus injection. Six hours after i.t. challenge the animals were killed in a CO 2 chamber and the thoracic cavity was opened and washed with 1 ml phosphate buffered saline (PBS). The pleural wash was collected with a pipette and used for analysis of the cellular infiltrate (total and differential leukocyte counts), PGE 2 and cytokine levels. The total number of leukocytes collected in the pleural wash was evaluated in a Neubauer chamber after dilution of a pleural wash sample in 2% acetic acid. The differential analysis of leukocytes was accomplished in cytosmears stained with May-Grunwald-Giemsa dye.
Treatments and Stimuli Intrathoracic challenge was performed with lipopolysaccharide (LPS; 250 ng/cavity), 5) formyl-methionyl-leucyl-phenylalanine (fMLP; 200 ng/cavity) 6) or platelet activating factor (PAF; 500 ng/cavity), 7) 1 h after treatment. Treatments consisted of an intraperitoneal (i.p.) injection of LAE of N. procerum (0.2, 2, 20 mg/kg i.p.) or acetyl salicylic acid (ASA; 100, 200, 500 mg/kg). All treatments were diluted in sterile saline immediately before use.
Lipid Body Staining and Enumeration To enumerate the lipid bodies within leukocytes, the pleural wash cytosmears were fixed in 3.7% formaldehyde diluted in Hank's Balanced Salt Solution (Ca 2ϩ /Mg 2ϩ -free HBSS; pH 7.4), rinsed in 0.1 M cacodylate buffer (pH 7.4), stained with 1.5% OsO 4 for 30 min, rinsed in distilled H 2 O, immersed in 1.0% thiocarbohydrazide for 5 min, rinsed in 0.1 M cadodylate buffer, re-stained with 1.5% OsO 4 for 3 min, rinsed in distilled water and then dried and mounted as previously described. 8) Cell morphology was observed and lipid bodies were enumerated by microscope under an oil immersion objective (100ϫ magnification). Twenty-five consecutively scanned leukocytes were evaluated and results were expressed as the number of lipid bodies per leukocyte.
Measurements of Pleural Fluid PGE 2 Pleural fluid Prostaglandin E 2 (PGE 2 ) concentration in the cell supernatant was assayed in duplicate by enzymatic immunoassay (EIA) according to the manufacturer's instructions (Cayman, Ann Arbor, MI, U.S.A.).
Murine Macrophage Cultures Mice were intraperitoneally injected with 2 ml of 3% thioglycollate. On day 3, the peritoneal cells were obtained by peritoneal lavage with 5 ml of HBSS, Ca 2ϩ and Mg 2ϩ free. These cells were washed twice and resuspended in Roswell Park Memorial Institute-1640 medium (RPMI-1640) supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were plated at a density of 1ϫ10 6 cells/well in a 24well culture plate (Falcon Labware, Lincoln Park, NJ, U.S.A.). Plates were incubated in a humidified atmosphere containing 5% CO 2 at 37°C for at least 1 h to allow macrophage adherence Then were washed by gentle agitation with HBSS Ca 2ϩ and Mg 2ϩ free and RPMI-1640 medium was added to the wells.
Induction of Cytokine Release by Macrophages in Vitro
Murine resident peritoneal macrophages (10 6 cells/ml in RPMI-1640) were pretreated with N. procerum LAE (2 or 0.2 mg/ml) for 15 min and then stimulated with LPS (500 ng/ ml) for 4 h. Cells were centrifuged and cytokines released in the supernatant were measured as described below.
In Vitro Induction of Lipid Body Formation withi Murine Macrophages Murine resident peritoneal macrophages (10 6 cells/ml in HBSS) recovered from the peritoneal cavity of naive mice were stimulated with PAF (1 mM), LPS (500 ng/ml) or vehicle (HBSS) at 37°C for 1 h. The leukocytes were pretreated with N. procerum LAE (2 or 0.2 mg/ml) for 15 min before stimulation. After stimulation, cells were prepared for lipid body evaluation, as described above.
Measurements of Pleural Fluid Cytokines Cell free supernatants were used for determination of IL-1b, KC, IL-10 and IL-6 levels within pleural fluid by ELISA using commercially available kits and following the instructions provided by the manufacturer (Duo set kit; R&D Systems, Mineapolis, MN, U.S.A.).
Human Neutrophil Purification Neutrophils were purified from fresh human blood obtained by venipuncture from healthy adult volunteers and collected in acidified citrate. After addition of 6% dextran 70 (McGaw, Irvine, CA, U.S.A.), red blood cells (RBC) were allowed to sediment for 1 h at room temperature. The leukocyte-rich supernatant was overlaid onto an equal volume of Ficoll-Paque gradient (Pharmacia, Piscataway, NJ, U.S.A.), and centrifuged at 400 g for 20 min. Polymorphonuclear leukocytes (PMN; 95% pure, with eosinophils as main contaminants) were recovered from the pellet and washed in Ca 2ϩ /Mg 2ϩ -free HBSS. Residual RBCs were lysed with hypotonic saline. 9) Human Neutrophil Chemotaxis Assay Migration experiments were performed using a 48-well microchemotaxis chamber (Neuro Probe, U.S.A.) and Toyo cellulose nitrate filters (3 mm pore), as described previously. 10, 11) PAF (10 Ϫ6 M) and RPMI-1640 medium containing bovine serum albumin (29 ml) were placed in the lower chamber compartment and 50 ml of the human neutrophil suspension (2.5ϫ10 5 cells/ 50 ml) was placed in the upper chamber compartment. Purified human neutrophils were pre-incubated with N. procerum LAE (0.01 mg/ml) or culture medium at 37°C in a 5% CO 2 atmosphere. Fifteen minutes after the pre-incubation period, the cells were placed in the chamber and incubated for 2 h at 37°C in a 5% CO 2 atmosphere. The filters were fixed and stained as described. 10) Human neutrophils found at 40 mm from the upper surface of the filter were counted in 15 consecutive high power fields (HPF).
In Vitro Induction of Lipid Body Formation within Human Neutrophils Purified human blood neutrophils (10 6 cells/ml of HBSS) were stimulated with LPS (500 ng/ml) or vehicle (HBSS) at 37°C for 1 h. The leukocytes were pretreated with N. procerum LAE (0.2 mg/ml) for 15 min before stimulation. After stimulation, cells were prepared for lipid body evaluation, as described above.
Statistical Analysis Results were represented as mean Ϯstandard error of mean (S.E.M.). The statistical analysis involving two groups was done using Student's t test. ANOVA followed by Neuman-Keuls Student test was used to compare three or more groups. The results were considered significant with values of pϽ0.05.
RESULTS

N. procerum LAE Inhibits LPS-Induced Neutrophil
Migration and PGE 2 Production in Vivo As previously demonstrated, 5, 12) the injection of LPS (250 ng/cavity) induced rapid influx of neutrophils as noted 6 h after LPS stimulation. Confirming our previous results, 1) pre-treatment with N. procerum LAE (0.2, 2, 20 mg/kg, i.p.) inhibited in a dosedependent manner the neutrophil accumulation induced by LPS ( Fig. 1 ). As shown in Fig. 1B , in vivo LPS stimulation also triggers PGE 2 production within 6 h. Consistent with N. procerum LAE ability to inhibit cyclooxygenase-2 (COX-2) in vitro, 1) here we demonstrate that in vivo LPS-induced pleural PGE 2 production was also sensitive to N. procerum LAE pre-treatment in a dose-dependent manner.
N. procerum LAE Potently Inhibits LPS-Induced Lipid Body Formation within Pleural Leukocytes in Vivo
Lipid bodies are sites for compartmentalized eicosanoid formation that increase in numbers within leukocytes after different inflammatory insults including LPS stimulation. 8) Increased lipid body numbers within a recruited cell can be used as a marker of leukocyte activation. As shown in Fig N. procerum LAE Inhibits the LPS-Induced Production of Inflammatory Cytokines in Vivo It is well known that LPS triggers inflammation in part by inducing release of cytokines from inflammatory cells, such as macrophages bearing Toll like receptor-4 (TLR-4). 13) In order to evaluate the mechanisms involved in N. procerum LAE ability to impair LPS-induced neutrophilia, we investigated whether this extract was able to affect cytokine production on LPS-induced pleurisy. As shown in Fig. 3 , LPS induced both IL-1 and IL-6 release in mice pleural fluid 6 h after i.t. injection. Pre-treatment with N. procerum LAE (2 mg/kg) significantly decreased the levels of IL-1 ( Fig. 3A ) and IL-6 ( Fig. 3B ) recovered from the pleural wash of LPS-stimulated animals. In contrast, LPS-induced secretion of these cytokines (IL-1 and IL-6) and others (IL-10, KC and tumor necrosis factor (TNF)) in vitro by cultured mice peritoneal macrophages was not affected by N. procerum LAE, indicating that the cellular target of N. procerum LAE responsible in vivo for cytokine production may not be the resident macrophages, but possibly migrating cells. Of note, although N. procerum LAE failed to inhibit macrophage cytokine release, these cells are sensitive to N. procerum LAE. As shown in Table 1 , N. procerum LAE significantly inhibited LPS-induced formation of new lipid bodies within macrophages, but did not alter the basal numbers of lipid bodies found within non-stimulated macrophages (data not shown).
PAF-and fMLP-Induced Pleural Neutrophil Accumulation Were Sensitive to Inhibition by N. procerum LAE PAF and fMLP were described as important inductors of in vivo neutrophilic reaction, including mice pleurisies. 6, 14) As shown in Fig. 4 , N. procerum LAE (2 mg/kg) abolished both fMLP-and PAF-induced neutrophil accumulation in the mouse pleural cavity noted within 6 h (Figs. 4A, B , respectively).
N. procerum LAE Inhibits Human Neutrophil Function
in Vitro In addition to inhibiting neutrophil accumulation in vivo, N. procerum LAE also demonstrated a potent inhibitory effect on human neutrophil chemotactic activity in vitro. PAF is a potent chemotactic agent for human neutrophils in vitro. 11) As shown in Fig. 5 , PAF (10 Ϫ6 M) induced an important chemotactic effect on human neutrophils assayed in a Boyden chamber. Pre-incubation of neutrophils with N. procerum LAE (0.01 mg/ml) completely inhibited PAF-induced neutrophil chemotaxis, without affecting neutrophil chemokinesis since N. procerum LAE did not modify random migration of non-stimulated neutrophils (Fig. 5 ). In addition, as shown in Table 2 , N. procerum LAE blocked formation of new cytoplasmic lipid bodies within human neutrophils induced in vitro by PAF or LPS, suggesting that N. procerum LAE targets not only the locomotory machinery of neutrophils, but also a more critical step of neutrophil activation. Of note, basal numbers of cytoplasmic lipid bodies found within non-stimulated neutrophils were not modified by N. procerum LAE treatment ( Table 2) .
DISCUSSION
The aqueous crude extract prepared from the leaves of the bromeliad Nidularium procerum was shown to have a potent analgesic and anti-inflammatory activity in surrogate models of pain and inflammation. 1) The results obtained in the present study confirm the potent anti-inflammatory effects on LPS-induced neutrophilic reaction and reveal the possible mechanisms responsible for this effect.
Bacterial lipopolysaccharide (LPS) is an active fragment of the outer membrane of Gram-negative bacteria that has been used as an important tool to study the physiopathology of the inflammatory process. Neutrophil migration is a hallmark of the acute inflammatory process and is specially prominent after LPS challenge. 5, 12, 15, 16) Following recognition by TLR4 and activation of TLR signaling pathways, LPS induces not only the production of prostanoids but also the production and release of an array of cytokines that are essential for the development of the subsequent inflammatory process. 17) The pro-inflammatory cytokines, TNF, IL-1, IL-6, Macrophage inhibitory protein-1a MIP-1a, and MIP-1b play pivotal roles in stimulating the early stages of acute inflammation, including the recruitment and activation of inflammatory cells like neutrophils, stimulation of endothelial cell activation, and direct cytotoxicity. [18] [19] [20] [21] The finding that N. procerum LAE dose-dependently inhibits LPS-induced neutrophil accumulation in the mouse pleural cavity, reinforces our previous results 1) and clearly demonstrates the anti-inflammatory activity of this extract. The multistep process underlying the mechanisms involved in the development of endotoxin triggered tissue neutrophilia depends on at least three combined cellular components: (i) resident cells that primarily recognize the LPS; (ii) the chemoattractants/cytokines produced in situ (e.g., PAF, MIP-1a and KC); and (iii) the transmigrating and activated neutrophils themselves. When administered to LPS-stimulated mice, N. procerum LAE inhibited pleural neutrophilia and activation by a mechanism that appeared to depend on local events of endotoxemic inflammatory response, such as production of cytokines/chemo-attractants and/or function of transmigrating neutrophils.
The ability of N. procerum LAE to inhibit neutrophil accumulation can be partially explained by a mechanism dependent on N. procerum LAE-driven inhibition of LPS-induced in situ production of pro-inflammatory cytokines, including IL-1 and IL-6. Although production of chemokines is impaired by N. procerum LAE treatment, its cell target still needs to be defined since macrophages the most probable cell candidate do not appear to be the cytokine-producing cell sensitive to N. procerum LAE. The secretion of a variety of cytokines, including IL-1, IL-6, KC, IL-10 and TNF, by mouse macrophages stimulated in vitro with LPS was not modified by N. procerum LAE treatment. Different pleural resident cells of LPS-stimulated mice, such as mast cells or mesothelial cells, could represent the targets of N. procerum LAE.
We further investigated potential direct effects on neutrophils by evaluating N. procerum LAE effects on in vitro locomotory activity of neutrophils induced by PAF and fMLP. It is well known that local PAF action is strongly implicated in the early tissue neutrophil accumulation induced by LPS 5) ; PAF and PAF related molecules are able to directly attract neutrophils to the site of inflammation, 14) although evidence exists that this effect is dependent on the generation of leukotrienes in vivo. 9, 22, 23) On the other hand, fMLP unlike LPS and PAF, recruits neutrophils to inflamed tissues by a direct mechanism independent of lipid mediator and protein synthesis. 15, 24) N. procerum LAE inhibited both in vitro chemotaxis and in vivo pleural recruitment of neutrophils induced by PAF or fMLP. Therefore, the N. procerum LAE actual cell target within endotoxemic inflammation appears to be the neutrophils themselves, which have their motility machinery disrupted. It is noteworthy that N. procerum LAE also inhibit an other important inflammatory function of neutrophils the formation of new cytoplasmic lipid bodies indicating that the N. procerum LAE intracellular target within neutrophils is an upstream step common to cell motility and lipid body genesis.
Lipid bodies are non-membrane-bound, lipid-rich cytoplasmic domains that characteristically increase in number within leukocytes associated with the inflammatory process. 25) For instance, lipid body numbers are increased in eosinophils from patients with hypereosinophilic syndrome, 26) in leukocytes from inflammatory arthritis 25) and sepsis, 8) and from bronchoalveolar lavage of patients with acute respiratory distress syndrome, 27, 28) Lipid bodies are candidates to play a major role in the formation of eicosanoid mediators during inflammation as they are sites of localization of several enzymes related to eicosanoid metabolism including COX-2, 5lipoxygenase, phospholipase A2, mitogen-activated protein kinase and phosphatidylinositide 3-kinase. 25, [29] [30] [31] In addition, agents that inhibit lipid body formation in vitro inhibited the priming response for enhanced eicosanoid release. 14) Also yangambin, a competitive PAF receptor antagonist extracted from the Brazilian plant Ocotea duckei VATTIMO, is able to inhibit PAF-induced lipid body formation in mice peritoneal macrophages. 32) The inhibition of lipid body formation has been proposed as a novel strategy for anti-inflammatory therapies. 25, 28) In this respect, ASA and other nonsteroidal anti-inflammatory drugs (NSAIDs) were described as effective inhibitors of leukocyte lipid body formation, 25, 28) and this effect was shown to be independent of cyclooxygenase inhibition. 25, 28) Moreover, PAF and cis-fatty acids stimulate numbers of lipid bodies correlated with enhanced levels of leukotrienes and prostaglandins in human PMNs and eosinophils. ASA and various NSAIDs inhibit lipid body formation and also inhibit the enhanced formation of lipoxigenase-and cyclooxygenase-derived eicosanoids. 25) Here, we showed that N. procerum LAE is able to block LPS-induced lipid body formation both in vitro and in vivo within neu-1014 Vol. 28, No. 6 trophils. Moreover, LPS-induced in vivo production of PGE 2 was decreased by N. procerum LAE treatment, suggesting that inhibition of lipid body formation may affect the production of prostanoids after LPS stimulation. Nevertheless, LPS is a potent stimulus for COX-2 expression 33) and one must take into account that N. procerum LAE has been previously shown to selectively inhibit COX-2 activity in an in vitro assay using cells overexpressing COX-2, 1) which could explain the reduction in PGE 2 production. In fact, our experiments show that doses of N. procerum LAE able to completely inhibit lipid bodies formation are not enough to significantly reduce PGE 2 production, indicating that an additional effect might take place in parallel to inhibition of lipid body formation to reduce the formation of prostanoids.
Inasmuch as neutrophils are implicated as the major players of endotoxemic disorders, our results point toward the Brazilian bromeliaceae N. procerum as a phyto-pharmacological candidate for novel alternative anti-inflammatory therapies. N. procerum LAE exerts its anti-neutrophilic effects by interfering at different levels with the capacity of the host to respond to injury caused by endotoxin. Specifically, the mechanism of N. procerum LAE-driven inhibition of endotoxin-induced neutrophilia involves the inhibition of at least 3 key events: local cytokine production, neutrophil migratory activity and neutrophil activation.
